PARIET* (RABEPRAZOLE) RECEIVES APPROVAL FOR
|Eisai Public Relations Department
Eisai Co., Ltd.
|+81 3 3817 5120|
Global Pharmaceutical Communications
Johnson & Johnson
|+32 14 60 54 09|
|+44 20 7300 62 94|
Eisai Co., Ltd. is a research-based human health care company which discovers, develops and markets products in more than 30 countries. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care system. The company reported sales of over $2.9 billion in 2000 with approximately 14 percent of sales spent for research and development.
Further information on Eisai can be found at http://www.eisai.co.jp
Janssen Pharmaceutica N.V. is a wholly owned subsidiary of Johnson & Johnson, the world's most comprehensive manufacturer of healthcare products and related services. Known as Janssen-Cilag in most countries, Janssen is a leader in the research and development of therapies for gastrointestinal disorders with 32 affiliates worldwide. Other areas of research focus include analgesia, neurology and psychiatry.
Further information on Janssen-Cilag can be found at: http://www.janssen-cilag.com
|Symptomatic GORD is also sometimes referred to as non erosive reflux disease. In Europe, Pariet* is currently indicated for the treatment of:
|And, when used in combination with appropriate antibacterial treatments, for the:
Rabeprazole sodium was discovered by Eisai Co., Ltd. Janssen Pharmaceutica N.V. and Eisai Co., Ltd. have a strategic alliance in which Eisai and Janssen-Cilag co-promote the drug in Germany and the U.K. In the US rabeprazole sodium is co-promoted under the brand name AcipHex by Eisai Inc. and Janssen Pharmaceutica Inc. Pariet* is available through Janssen-Cilag in most other countries excluding Japan and some Asian countries.
Eisai Ltd. in the U.K. submitted a Type II variation application for Pariet* to the MCA in March 2001. Eisai Inc. recently submitted a supplemental New Drug Application (sNDA) for AcipHex to the U.S. Food and Drug Administration for the treatment of symptomatic gastroesophageal reflux disease (GERD, also known as GORD in Europe).
* Pariet*/Aciphex are trademarks of Eisai Co., Ltd., Tokyo, Japan.
|1)||Talley, NJ. Presentation made at an international workshop: Gastroenterology into the next Millennium. 13 March 1999; Madrid, Spain.|
|2)||Dent, J. Gastro-esophageal reflux disease. Digestion. 1998; 59: 433-445.|
|3)||Carlsson R, Dent J, Watts R et al. Gastro-esophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. Euro J Gastroenterol Hepatol. 1998; 10: 119-124.|